[New entities in pathological classification and new therapeutic options in renal cell carcinoma].
Therapy for renal cell carcinoma has made considerable progress in the past few years. The aims of this review are to update the pathological classification of this tumor and discuss predictive factors for tumor response and survival in the case of metastasis as well as the place of immunotherapy with interleukine-2 and/or interferon alpha . Furthermore, we will review new therapeutic options and current results on allogeneic stem cell transplantation with non-myeloablative conditioning and HLA genoidentical donors. Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma.
Bay
Jacques-Olivier
JO
Département d'oncologie médicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand. olivier.bay@cjp.fr
Penault-Llorca
Frédérique
F
Ravaud
Alain
A
Chevreau
Christine
C
Négrier
Sylvie
S
Escudier
Bernard
B
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000503:physiopathology* / Q000628:therapy*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000503:physiopathology* / Q000628:therapy*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D033581:Stem Cell Transplantation; D013534:Survival; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; D011505:Protein-Tyrosine Kinases